TORNTPHARM
PharmaceuticalsTorrent Pharmaceuticals Ltd.
It was started in 1959 by U N Mehta as Trinity Laboratories, and then the company changed its name to the one used currently in the year 1971.
TPL is the flagship company of the Torrent group, a leader in cardiovascular and central nervous system segments. It also has a presence in gastrointestinal, diabetology, and the sections of pain management.
Its prime manufacturing facilities are located at Indrad (Gujarat), and Baddi (Himachal Pradesh) and these units have received many certifications for its quality management such as ISO 9001, ISO 14001 and OHSAS 18001, and ISO/IEC– 17025 and more.
The company's manufacturing plant in Indrad produces a bulk of drugs, APIs, the formulation in the form of tablets, capsules, and vials. The annual production capacity of this particular plant is 6000 million kg of formulations and 15000 kg of bulk drugs/APIs.
Whereas the Baddi plant has a manufacturing capacity of approximately 3600 million tablets, 400 million capsules, and 18 million oral liquid bottles p. a.
In India, this particular company has at least 11 sales and marketing divisions and 1000 product registrations across 50 different countries that include US Latin America, Russia, Europe, Japan, and others.
- Trades at a P/E of 67.2, with a return on equity (ROE) of 24.2%.
- TORNTPHARM is trading above 4 of 5 of its key moving averages (10/20/50/100/200-DMA) — a bullish technical setup.
- Year-to-date it is up 32.77%, and up 33.05% over the past year.
- At ₹4,961.50 it sits about 92% of the way up its 52-week range (₹3,480.60–₹5,085.80).
- Offers a dividend yield of 0.89%.
- Market capitalisation stands at ₹1.68L Cr.
Shareholding data syncs daily.
| Year | Revenue | Net Profit | EPS | NPM |
|---|---|---|---|---|
| Mar 2023 | ₹7,695 Cr | ₹1,052 Cr | ₹31.08 | 13.67% |
| Mar 2022 | ₹6,742 Cr | ₹991 Cr | ₹58.59 | 14.7% |
| Mar 2021 | ₹8,005 Cr | ₹1,252 Cr | ₹73.98 | 15.64% |
| Mar 2021 | ₹8,005 Cr | ₹1,252 Cr | ₹73.98 | 15.64% |
| Mar 2020 | ₹7,939 Cr | ₹1,025 Cr | ₹60.55 | 12.91% |
| Mar 2020 | ₹7,939 Cr | ₹1,025 Cr | ₹60.55 | 12.91% |
| Mar 2019 | ₹7,673 Cr | ₹436 Cr | ₹25.78 | 5.68% |
| Mar 2019 | ₹7,673 Cr | ₹436 Cr | ₹25.78 | 5.68% |
| Mar 2018 | ₹5,950 Cr | ₹678 Cr | ₹40.07 | 11.39% |
| Mar 2017 | ₹5,816 Cr | ₹934 Cr | ₹55.16 | 16.06% |
| Mar 2016 | ₹6,687 Cr | ₹1,733 Cr | ₹102.41 | 25.92% |
| Mar 2015 | ₹4,636 Cr | ₹751 Cr | ₹42.12 | 16.2% |
| Company | P/E | Book Value | Sales Growth |
|---|---|---|---|
| SUNPHARMA SUN PHARMACEUTICAL INDUSTRIES LTD. | 39.1 | ₹98.33 | 10.1% |
| MARKSANS MARKSANS PHARMA LTD. | 23.8 | ₹11.85 | 5.8% |
| MOREPENLAB MOREPEN LABORATORIES LTD. | 20.81 | ₹6.43 | 16.6% |
| NEULANDLAB NEULAND LABORATORIES LTD. | 23.48 | ₹542.16 | 9.35% |
| GUFICBIO Gufic BioSciences Ltd. | 24.16 | ₹10.85 | 20.41% |
| DIVISLAB DIVI'S LABORATORIES LTD. | 41.01 | ₹266.77 | 9.47% |
| DRREDDY DR.REDDY'S LABORATORIES LTD. | 19.73 | ₹852.69 | 1.07% |
| RPGLIFE RPG LIFE SCIENCES LTD. | 17.14 | ₹105.02 | 5.73% |
| GLAND Gland Pharma Ltd | 53.6 | ₹242.00 | — |
| ZYDUSLIFE Zydus Lifesciences Ltd | 8.23 | ₹166.00 | 5% |
| SMSPHARMA SMS PHARMACEUTICALS LTD. | 9.58 | ₹42.07 | -8.73% |
| CIPLA CIPLA LTD. | 15.36 | ₹209.71 | 0.7% |
| Date | Client | Type | Qty | Price |
|---|---|---|---|---|
| 25 Oct 2022 | ISHARES CORE EMERGING MARKETS MAURITIUS CO | SALE | 86,000 | ₹1,567.30 |
| 25 Oct 2022 | ISHARES CORE MSCI EMERGING MARKETS ETF | PURCHASE | 86,000 | ₹1,567.30 |
| 17 Oct 2022 | ISHARES CORE EMERGING MARKETS MAURITIUS CO | SALE | 1,35,148 | ₹1,595.05 |
| 17 Oct 2022 | ISHARES CORE MSCI EMERGING MARKETS ETF | PURCHASE | 1,35,148 | ₹1,595.05 |
| 11 Oct 2022 | ISHARES CORE EMERGING MARKETS MAURITIUS CO | SALE | 1,32,154 | ₹1,593.65 |
| 11 Oct 2022 | ISHARES CORE MSCI EMERGING MARKETS ETF | PURCHASE | 1,32,154 | ₹1,593.65 |
| 19 Sept 2022 | ISHARES CORE EMERGING MARKETS MAURITIUS CO | SALE | 89,889 | ₹1,478.70 |
| 19 Sept 2022 | ISHARES CORE MSCI EMERGING MARKETS ETF | PURCHASE | 89,889 | ₹1,478.70 |
| 01 Aug 2022 | ISHARES INDIA INDEX MAURITIUS COMPANY | SALE | 1,20,521 | ₹1,528.80 |
| 01 Aug 2022 | ISHARES MSCI INDIA ETF | PURCHASE | 1,20,521 | ₹1,528.80 |
| 18 Jul 2022 | ISHARES INDIA INDEX MAURITIUS COMPANY | SALE | 1,20,878 | ₹1,518.00 |
| 18 Jul 2022 | ISHARES MSCI INDIA ETF | PURCHASE | 1,20,878 | ₹1,518.00 |
Related stocks
Fundamentals, financials & technicals sourced from niftytrader.in, cached and refreshed periodically.